Moderna (MRNA) Receivables - Other: 2017-2025
Historic Receivables - Other for Moderna (MRNA) over the last 7 years, with Sep 2025 value amounting to $40.0 million.
- Moderna's Receivables - Other fell 20.00% to $40.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.0 million, marking a year-over-year decrease of 20.00%. This contributed to the annual value of $59.0 million for FY2024, which is negligibly% changed negligibly from last year.
- According to the latest figures from Q3 2025, Moderna's Receivables - Other is $40.0 million, which was down 34.43% from $61.0 million recorded in Q2 2025.
- Moderna's Receivables - Other's 5-year high stood at $69.0 million during Q1 2023, with a 5-year trough of $6.0 million in Q3 2021.
- Moreover, its 3-year median value for Receivables - Other was $59.0 million (2024), whereas its average is $56.6 million.
- As far as peak fluctuations go, Moderna's Receivables - Other plummeted by 40.07% in 2021, and later surged by 800.00% in 2022.
- Quarterly analysis of 5 years shows Moderna's Receivables - Other stood at $51.0 million in 2021, then rose by 19.61% to $61.0 million in 2022, then fell by 3.28% to $59.0 million in 2023, then remained steady at $59.0 million in 2024, then declined by 20.00% to $40.0 million in 2025.
- Its Receivables - Other stands at $40.0 million for Q3 2025, versus $61.0 million for Q2 2025 and $53.0 million for Q1 2025.